Interestingly, Lin et al. reported that in prostate cancer cell lines wild-type but not mutant P53 can significantly inhibit STAT3 activity, whereas it has also been reported that STAT3 can bind to P53 promoter and inhibit the P53 gene transcription rate [18], [19]. The gene discussed is TP53; the disease is prostate carcinoma.